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Abstract
Background: Annual trivalent influenza vaccines (TIV) containing three influenza strains (A/H1N1, A/H3N2, and one B)
have been recommended for the prevention of influenza. However, worldwide co-circulation of two distinct B lineages
(Victoria and Yamagata) and difficulties in predicting which lineage will predominate each season have led to the
development of quadrivalent influenza vaccines (QIV), which include both B lineages. Our analysis evaluates the public
health benefit and associated influenza-related costs avoided which would have been obtained by using QIV rather
than TIV in Australia over the period 2002–2012.
Methods: A static model stratified by age group was used, focusing on people at increased risk of influenza as defined
by the Australian vaccination recommendations. B-lineage cross-protection was accounted for. We calculated the
potential impact of QIV compared with TIV over the seasons 2002–2012 (2009 pandemic year excluded) using
Australian data on influenza circulation, vaccine coverage, hospitalisation and mortality rates as well as unit costs, and
international data on vaccine effectiveness, influenza attack rate, GP consultation rate and working days lost. Third-party
payer and societal influenza-related costs were estimated in 2014 Australian dollars. Sensitivity analyses were conducted.
Results: Using QIV instead of TIV over the period 2002–2012 would have prevented an estimated 68,271 additional
influenza cases, 47,537 GP consultations, 3,522 hospitalisations and 683 deaths in the population at risk of influenza.
These results translate into influenza-related societal costs avoided of $46.5 million. The estimated impact of QIV was
higher for young children and the elderly. The overall impact of QIV depended mainly on vaccine effectiveness and the
influenza attack rate attributable to the mismatched B lineage.
Conclusion: The broader protection offered by QIV would have reduced the number of influenza infections and its
related complications, leading to substantial influenza-related costs avoided.
Keywords: Influenza, Vaccine, Quadrivalent, Australia, Cost, Benefit, Public health
Background
Influenza is an acute infectious respiratory disease in
humans, caused by influenza viruses A and B. In young
children, the elderly, or persons with other serious
chronic conditions, influenza can lead to complications
of the underlying condition, pneumonia or even death
[1]. Worldwide, influenza causes 3–5 million cases of
severe illness and between 250,000–500,000 deaths every
year [2]. In Australia, influenza has been estimated to
cause on average 310,000 General Practitioner (GP)
consultations and 18,400 hospitalisations annually be-
tween 1998 and 2005, leading to an annual expenditure
of 115 million Australian dollars (A$) for the health care
system [3].
Vaccination remains the most effective measure for
preventing influenza and its complications [4, 5]. In
Australia, influenza vaccination is recommended for
everyone from 6 months of age [6], and is provided free
under the National Immunisation Program to people at
increased risk of influenza complications i.e. all adults
aged 65 and older, Australian Aboriginal and Torres
Strait Islander people aged between 6 months and 5 years
or older than 15 years, pregnant women and all persons
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aged 6 months and older with specific comorbidities
predisposing to severe influenza [7].
Immunisation against seasonal influenza using trivalent
influenza vaccines (TIV) is currently recommended by
public health policy makers around the world [8–10]. TIV
contains strains of two influenza A sub-types (one each of
H1N1 and H3N2), and one lineage of influenza B (Victoria
or Yamagata), based on WHO recommendations [11].
However, over the decade 2000 through 2011 in
Australia, the two distinct lineages of influenza B have
been co-circulating at varying levels and with no regular-
ity, resulting in mismatches between the circulating
lineage and the vaccine in six of the 12 seasons [12].
More recently, during the early stages of the 2015 influ-
enza season in New South Wales, 19 % of all influenza
specimens tested positive were from the Victoria lineage,
which was not included in TIV [13]. Two recent meta-
analyses have demonstrated that the level of protection
induced by TIV is sub-optimal when there is a mismatch
between the circulating influenza B lineage and the
actual B lineage included in the vaccine [14, 15].
Recently, quadrivalent influenza vaccines (QIV) in-
cluding both B lineages in addition to both A subtypes
have been developed in response to the evolution in
influenza epidemiology. The potential impact of QIV in
the US was estimated by Reed et al. [16], who consid-
ered a hypothetical scenario where QIV would have
replaced TIV over ten influenza seasons. The study esti-
mated that, within the seasons 2001–2002 to 2008–
2009, QIV might have additionally prevented 340,000
influenza cases, 2,700 hospitalisations and 170 deaths
per year compared with TIV. Another study by Lee et al.
[17] expanded upon the results of Reed et al. to estimate
the economic impact of QIV in the US and concluded
that the use of QIV instead of TIV could substantially
decrease influenza-related costs borne by society and
health care payers.
In Australia, QIV was first approved by the Therapeutic
Good Administration for the 2015 influenza season [18].
The objective of this study was therefore to estimate the
additional benefit of using QIV rather than TIV, on
influenza-related health and economic outcomes during
the period 2002–2012 in Australia.
Methods
Two different vaccination strategies were compared: the
actual situation where TIV was administered over the
period 2002–2012, and a second strategy where QIV would
have been used instead of TIV during the same period.
Model description
We used an age-stratified, static model. For each strategy,
the number of influenza cases, GP consultations, working
days lost, hospitalisations and deaths related to influenza,
as well as associated costs, were estimated for each season
over the period 2002–2012. Season 2009 was excluded
from the scope due to the H1N1 pandemic, which
rendered the year atypical and would have biased the esti-
mated season-specific influenza attack rate. The potential
public health and economic impact of QIV compared with
TIV was captured as the difference in outcomes between
the two strategies.
The expected influenza attack rate attributable to a
specific virus strain j (j =A, B/Yamagata, B/Victoria) in a
population partially vaccinated with a vaccine i (i =QIV,
TIV) for a given year was computed as follows:
ARi;j ¼ ARno vac⋅ pj⋅ 1−VC:VEi=j
 
Where ARno vac denotes the expected influenza attack
rate without vaccination, pj the proportion of strain j, V
C the vaccine coverage rate and VEi=j the effectiveness
of vaccine i against strain j. The other influenza-related
outcomes were assumed to be proportional to the num-
ber of influenza infections.
To estimate the impact of QIV vs. TIV on resource
use and influenza-related costs, the numbers of GP
visits, hospitalisations and lost working days avoided
were multiplied with corresponding unit costs. The
economic impact was estimated by taking into account
third-party payer (TPP) costs (GP consultations, hospita-
lisations), and societal costs (i.e. the sum of TPP costs
and the loss of productivity due to work absenteeism), in
2014 Australian dollars ($). The model structure is
presented in Fig. 1.
Data inputs
Population
The population of interest was defined as the population
eligible for free vaccination under the National Immun-
isation Program [7], including everyone older than
65 years and individuals aged 6 months to 64 years with
at least one risk factor as defined in the Australian
Immunisation Handbook [6], namely: pregnant women,
persons with cardiovascular diseases, obesity, chronic
respiratory conditions, chronic neurological conditions,
metabolic diseases including diabetes mellitus, renal
dysfunction, and immunocompromised conditions such
as HIV and cancer.
To account for both local vaccination recommenda-
tions and the heterogeneity in the disease burden of
influenza, the model was stratified into five age groups
(6–59 months, 5–17 years, 18–49 years, 50–64 years,
65 years and older). For people aged from 6 months to
64 years, the analyses focused on people with risk
factors.
To estimate the proportion of the general population
with at least one risk factor, prevalence data were
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collected mainly from the 2012 Australian Health Survey
[19], combined with other sources [20, 21], and were
corrected to avoid double-counting when data were
available. The population size (see Table 1) was assumed
to be constant across the period, corresponding to the
2012 population estimates [22].
Influenza attack rate
Average annual attack rates in an unvaccinated popula-
tion were taken from the pooled control arms of clinical
trials presented in Cochrane reviews for healthy chil-
dren, healthy adults and the elderly [23–25]. These rates
were then distributed across the influenza seasons using
the following formula:
ARseason;group ¼ ARgroup  Vseason= Average V seasonð Þð Þ
where ARseason; group denotes the age- and season-specific
influenza attack rate, ARgroup the average attack rate for
the given age group and V season the season-specific
severity coefficient, defined as the year-specific number
of influenza cases notified within the National Notifiable
Diseases Surveillance System [26], adjusted by the number
of yearly notifications from the other notified diseases to
account for possible variations in the collection and test-
ing capacities of the surveillance system.
Strain distribution
The distribution of influenza strains for the years 2002
to 2011 was estimated using data from the WHO
Collaborating Centre for Reference and Research on
Influenza in Melbourne, Australia [27]. Estimates for
2012 were derived from laboratory confirmed data from
the Global Influenza Surveillance and Response System
in Australia [28]. B lineages contained in the TIV formu-
lation for Australia each year, corresponding to the
southern hemisphere formulation, were retrieved from
the World Health Organization website [11]. Influenza
circulation by season is presented in Table 2.
Vaccine coverage and effectiveness
Coverage rates [29, 30], as well as strain-specific vaccine
effectiveness, were assumed to be constant over time.
The average effectiveness of TIV against matched and
mismatched B lineages was estimated in a meta-analysis
in which B lineage cross-protection was found to be
approximately 68 % of the effectiveness against the
matched B lineage in adults (i.e. vaccine efficacy was
77 % against matched B lineage and 52 % against
mismatched B lineage) [14]. Vaccine effectiveness rates
by strain and age group were sourced from Clements et al.
[31] (see Table 1). Vaccine effectiveness against both B lin-
eages for QIV was assumed to be the same as the vaccine
effectiveness of TIV against the matched B lineage.
Resource use and economic inputs
The probability of an influenza infection requiring a GP
consultation was derived from a US cost-effectiveness
study in which the probability for high-risk patients was
assumed to be twice that of low-risk patients [32].
Average hospitalisation rates were taken from Newall
and Scuffham [3] in which excess hospitalisation (coded
as influenza/pneumonia and other respiratory illness)
rates by age group attributable to influenza in Australia
were estimated using regression models based on data
from 2000 to 2006. Mortality rates were based on the
excess death (coded as respiratory or circulatory) rate
presented in Newall et al. [33] for the elderly in Australia
with an extrapolation to other age groups using the age-
specific mortality rates of Molinari et al. [32].
The cost of a GP consultation was sourced from the
Medical Benefits Schedule [34] while hospitalisation costs
were estimated using reported costs from Diagnosis-
Related Groups for respiratory conditions in the National
Estimating the attack rate 
by year, strain, age group 
for both vaccination 
strategies  (TIV or QIV)
Population targeted by Australian vaccination recommendations
Influenza A 
cases
Influenza B cases 
(matched B lineage)
Influenza B cases 
(mismatched B lineage)













outcomes and associated 
costs due to increased 
effectiveness of QIV 
compared with TIV
Fig. 1 Model structure. Abbreviations: GP: general practitioner; TIV: trivalent influenza vaccine; QIV: quadrivalent influenza vaccine
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1,331,660 13.0 % 173,778a 41.3 % 59 % 66 % 67 % 18.8 % 91.0 % $37 106 $3,944 0.6 0.64 $192
Children with RF
(5–17 years)
3,673,678 13.9 % 509,239a 41.3 % 61 % 75 % 67 % 16.5 % 63.6 % $37 16 $4,811 0.1 0.64 $192
Adults with RF
(18–49 years
10,220,627 21.8 % 2,223,249a 36.2 % 61 % 77 % 68 % 3.6 % 62.6 % $37 31 $5,644 0.3 2.59 $784
Adults with RF
(50–64 years)
4,114,452 31.5 % 1,296,098a 36.2 % 61 % 73 % 67 % 3.6 % 62.6 % $37 91 $7,497 4.1 2.59 $784
Elderly (65 years
and older)
3,221,321 - 3,221,312 74.6 % 58 % 69 % 68 % 4.9 % 72.2 % $37 440 $10,141 91.3 0d $0d














Hospital Cost Data Collection Report 2011–2012 [35].
Costs were adjusted by age group using the average length
of stay from the Australian-refined diagnosis-related
groups data cubes [36] and inflated to 2014 rates [37].
The numbers of working days lost per GP consultation
for adults and young children were respectively taken
from a French study [38] reporting an average of 4
working days lost, and from an Italian study [39] in
which parental working days lost were estimated to be
0.98 days. These estimates were then adjusted with the
Australian labour force participation rate (64.8 %) [40]
to obtain the number of working days lost per GP
consultation. The cost of a working day lost was
assumed to be the median Australian daily wage for full-
time employees [41].
The cost of vaccination was not taken into account in
this analysis which is aimed at measuring the impact of
QIV on influenza burden, while assuming price parity
between QIV and TIV.
Sensitivity analyses
Sensitivity analyses were conducted to test the impact of
modelling assumptions and the uncertainty around
inputs.
First, we conducted two scenario analyses in which we
tested different assumptions for the model. In a first sce-
nario analysis (scenario 1), influenza attack rates were
assumed to be constant over the study period to test the
impact of the distribution of attack rates using the num-
ber of notified cases as a proxy of the season severity. In
a second scenario analysis (scenario 2), hospitalisation
and death rates in high-risk patients were adjusted using
ratios between high-risk patients and the general popula-
tion [42–44].
Second, we performed a univariate deterministic sensi-
tivity analysis to quantify the effects of the uncertainty
around data inputs on the number of avoided cases and
total societal costs avoided, in which each group of
parameters was varied one at a time to the lower and
upper bounds of the range of estimated values. Lower
and higher bound values used in the deterministic
sensitivity analyses were taken from published literature




Over the period 2002–2012, it was estimated that substi-
tuting QIV for TIV would have reduced the number of
influenza cases by over 68,000 in addition to the cases
avoided with TIV, leading to 47,500 GP consultations,
3,500 hospitalisations and 680 deaths avoided in
Australia (see Table 3). The majority (58.4 %) of influenza
cases would have been avoided in 2012 - a season with a
high attack rate, a relatively high B strain circulation
(30.5 %) and a very high B lineage mismatch (86.8 %).
Seasons 2002 and 2008 were also years associated with a
substantial impact of QIV, with around 5,800 and 13,500
influenza infections additionally avoided, respectively. The
avoided resource use was associated with a reduction of
influenza-related TPP costs of approximately A$ 36.5 mil-
lion over the period 2002–2012 compared with the TIV
strategy. Avoided hospitalisation costs represented 95 % of
total influenza-related TPP costs avoided. Productivity loss
avoided was estimated at A$ 10.0 million, representing
21.5 % of the A$ 46.5 million of additional societal costs
avoided. On average, over the five targeted population
subgroups, QIV was estimated to additionally prevent 92
influenza cases per 100,000 person-years, leading to
avoided influenza-related societal costs of A$ 62,700 per
100,000 person-years.
Table 2 Influenza circulation and B lineage included in TIV by influenza season
Season B lineage included
in TIV [11]
Influenza circulation [27, 28] B lineage
mismatcha
Number of influenza notified cases








2002 Yamagata 77.2 % 21.9 % 0.9 % High 5,626
2003 Victoria 99.2 % 0.2 % 0.6 % High 5,149
2004 Victoria 75.0 % 4.2 % 20.8 % High 2,718
2005 Yamagata 78.5 % 10.4 % 11.1 % Medium 5,541
2006 Victoria 65.6 % 32.9 % 1.5 % Low 3,597
2007 Victoria 94.7 % 1.2 % 4.1 % High 11,356
2008 Yamagata 36.7 % 32.4 % 30.9 % Medium 8,882
2010 Victoria 87.3 % 11.5 % 1.2 % Low 9,905
2011 Victoria 68.8 % 30.6 % 0.6 % Low 18,658
2012 Victoria 69.5 % 4.3 % 26.3 % High 32,274
TIV trivalent influenza vaccine, aLow: <33 %, Medium: [33 %; 66 %], High: >66 %
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Table 3 Number of avoided outcomes and associated cost offsets (in A$) for total recommended population (n = 7,423,675) by season
Outcomes avoided Influenza-related cost offsets
Influenza cases GP consultations Working days lost Hospitalisations Deaths Total TPP Total Societal
Total Rate per 100,000
population
Total Rate per 100,000
population
Total Rate per 100,000
population
Total Rate per 100,000
population
Total Rate per 100,000
population
Total Rate per 100,000
population
Total Rate per 100,000
population
2002 5,793 78 4,034 54 2,808 38 299 4.0 58 0.78 $3,097,560 $41,725 $3,946,994 $53,168
2003 155 2 108 1 75 1 8 0.1 2 0.02 $82,892 $1,117 $105,623 $1,423
2004 2,663 36 1,854 25 1,291 17 137 1.9 27 0.36 $1,423,708 $19,178 $1,814,127 $24,437
2005 2,707 36 1,885 25 1,312 18 140 1.9 27 0.36 $1,447,482 $19,498 $1,844,420 $24,845
2006 262 4 182 2 127 2 14 0.2 3 0.04 $140,054 $1,887 $178,461 $2,404
2007 2,209 30 1,538 21 1,070 14 114 1.5 22 0.30 $1,180,882 $15,907 $1,504,711 $20,269
2008 13,543 182 9,430 127 6,564 88 699 9.4 135 1.82 $7,241,013 $97,539 $9,226,692 $124,287
2010 544 7 379 5 264 4 28 0.4 5 0.07 $291,114 $3,921 $370,945 $4,997
2011 493 7 343 5 239 3 25 0.3 5 0.07 $263,571 $3,550 $335,849 $4,524
2012 39,902 538 27,784 374 19,341 261 2,058 27.7 399 5.38 $21,334,862 $287,389 $27,185,450 $366,199
Total 68,271 920 47,537 640 33,091 446 3,522 47.4 683 9.20 $36,503,138 $491,712 $46,513,271 $626,553














The overall impact of QIV was highest for the elderly
with 36,322 additional cases avoided versus 15,977 for
children and 15,971 for adults below 65 years of age (see
GP: general practitioner; TPP: third-party payer Table 4).
The elderly population accounted for 73 % of the
avoided influenza-related societal costs (A$ 34.0 million
of A$ 46.5 million for the entire population of interest).
Relative to population size, the impact of QIV in terms
of influenza cases and GP consultations avoided was
greatest for young children, with an average of 239 influ-
enza cases avoided per 100,000 person-years, leading to
217 GP consultations avoided. However, QIV was most
beneficial for the elderly in terms of hospitalisation and
mortality, with 10.1 additional hospitalisations and 2.10
additional deaths avoided per 100,000 person-years. The
economic impact of QIV was also highest for the elderly,
with mean influenza-related societal costs avoided of A$
105,560 per 100,000 person-years, the results being
driven by hospitalisation costs.
Finally, considering all influenza cases (A and B), it
was estimated that substituting QIV for TIV would have
reduced the number of influenza cases by 1.02 % on
average over the period 2002–2012 (2009 excluded). The
reduction ranged from 0.05 % in 2003 to 2.36 % in 2008,
with a reduction by 1.90 % in 2012, year with the most
influenza burden avoided (39,900 cases) with QIV
compared to TIV.
Sensitivity analyses
Results of the scenario analyses conducted showed
limited variations in outcomes (see Table 5). In scenario 1,
assuming constant attack rates for influenza over the
study period would lead to an overall reduction of 14 % of
QIV benefits compared to base case. When considering
an increased risk of hospitalisation and deaths for people
with risk factor (scenario 2), the number of hospitalisa-
tions and deaths avoided increased by 16 and 1 % respect-
ively while the total influenza-related societal costs
avoided increased by 8 % compared to base case.
Deterministic sensitivity analyses conducted for several
inputs on the number of influenza cases avoided and so-
cietal costs avoided showed that the variables with the
most impact on both outcomes were the vaccine effect-
iveness against mismatched B, the proportion of B strain
and the proportion of mismatched B lineage (see Fig. 2).
Age-specific influenza attack rates over the period was
the parameter with the largest impact on the number of
influenza cases avoided, estimated to be from 52,000 to
113,600 cases when considering the lower and higher
estimates, respectively.
Discussion
In recent years, the interest in QIV has grown mainly
because TIV only matches the predominant circulating
B lineage, and predicting which of the two B lineages
will circulate in any given season remains a challenge.
We modelled the impact of QIV compared to TIV
vaccination in Australia for five population groups at
increased risk of influenza complications over 10 sea-
sons, based on the same approach as in Reed et al. [16].
Overall, the use of QIV instead of TIV would have
substantially reduced the clinical burden of influenza
while avoiding thousands of hospitalisations and
hundreds of deaths associated with influenza over the 10
seasons in the population at risk of influenza. The
overall impact of QIV was highest for the elderly who
contributed the most to additional deaths avoided over
the period. Furthermore, assuming no increase in
vaccination costs, the use of QIV instead of TIV would
have avoided A$ 46.5 million in influenza-related soci-
etal costs over 10 years. The analyses suggested that cost
offsets would be higher in the elderly, being essentially
driven by hospitalisations, than in the other targeted
groups. The impact of QIV mainly depends on influenza
B strain circulation, and influenza B co-circulation of B/
Yamagata and B/Victoria is expected to continue in
upcoming influenza seasons [45].
Compared to the US study by Reed et al. [16], two
enhancements to the model were made, leading to more
accurate estimates of the public health impact and
influenza-related costs avoided. First of all, our analysis
accounted for TIV cross-protection against mismatched
B lineage. Secondly, the population was stratified to
account for differences in vaccination coverage, vaccine
effectiveness and risks of complications between groups.
These improvements to the model, along with influenza
circulation informed by data specific to Australia,
allowed us to provide more realistic estimates of the
benefits of QIV.
Contrary to our study, the study by Lee et al. [17]
included lifetime productivity loss in the event of death
in societal costs to assess the economic impact of QIV
based on the model by Reed et al. Influenza-related
societal costs avoided estimated by Lee et al. were sub-
stantially higher than those estimated in our analysis:
about US$ 110,000 per 100,000 persons in the general
US population, compared to approximately US$ 46,000
(US$ 1 = A$ 1.6). Clements et al. [31] estimated
influenza-related costs avoided associated with the use
of QIV in the US at US$ 41,000 (without vaccination
cost and lifetime productivity loss) for 100,000 people
accounting for cross-protection and using stratification.
In Australia, Newall and Scuffham [3] estimated that
around 310,000 GP visits and 18,400 hospitalisations an-
nually were due to influenza in the general population
over the period 1998–2005. In our study, when consider-
ing the entire Australian population, the model estimated
the number of hospitalisations under TIV at 14,700
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Influenza cases 4,153 239 11,824 232 10,240 46 5,731 44 36,322 113 68,271 92
GP consultations 3,780 217 7,520 148 6,410 29 3,588 28 26,239 81 47,537 64
Working days lost 2,400 138 4,776 94 16,616 75 9,299 72 0b 0b 33,091 45
Hospitalisations 23 1.3 11 0.2 86 0.4 143 1.1 3,257 10.1 3,522 4.7
Deaths 0 0.01 0 0.00 1 0.00 6 0.05 675 2.10 683 0.92
Influenza-related cost offsets
GP consultations $140,034 $8,058 $278,618 $5,471 $237,508 $1,068 $132,923 $1,026 $972,167 $3,018 $1,761,250 $2,372
Hospitalisations $92,186 $5,305 $54,790 $1,076 $487,832 $2,194 $1,075,050 $8,295 $33,032,031 $102,542 $34,741,889 $46,799
Income loss $726,069 $41,781 $1,444,619 $28,368 $5,026,395 $22,608 $2,813,051 $21,704 $0b $0b $10,010,133 $13,484
Total TPP $232,220 $13,363 $333,408 $6,547 $725,340 $3,263 $1,207,973 $9,320 $34,004,198 $105,560 $36,503,138 $49,171
Total Societal $958,288 $55,145 $1,778,027 $34,915 $5,751,735 $25,871 $4,021,024 $31,024 $34,004,198 $105,560 $46,513,271 $62,655














annually across targeted groups while the estimated
number of GP consultations per year was substantially
higher with 436,000 GP consultations per year. Recently,
Milne et al. [46] estimated, using a dynamic transmission
model, that QIV would have reduced hospitalisations and
deaths by 2.2 and 2.1 % respectively, compared with TIV
over 2001–2011 in Albany, Western Australia. Our model
however, estimated the reduction to be 2.4 and 3.7 %
respectively, over 2002–2012. These slightly higher rates
can be explained by a slightly different coverage rate
considered in our model (17.5 vs. 15 %) combined with
the inclusion of 2012, a year with high B mismatch.
30 40 50 60 70 80 90 100 110 120
% population with risk factor
Vaccine coverage rate
% mismatched B lineage
% influenza B among all strains
B lineage cross-protection (TIV)
Average influenza attack rate
Additional influenza cases avoided (in thousands)
A
20 25 30 35 40 45 50 55 60 65 70
Working days lost per GP consultation
Cost of GP consultation
% population with risk factor
GP consultation rate




% mismatched B lineage
% influenza B among all strains
B lineage cross-protection (TIV)
Total societal costs avoided (in millions A$)
High value Low value
B
Fig. 2 Deterministic sensitivity analyses on total influenza cases avoided (a) and societal cost offsets (b) over the period 2002–2012 (2009 excluded).
High value: results of the model when the parameter value is set to the lower bound of the parameter range. Low value: results of the model when
the parameter value is set to the upper bound of the parameter range. Example of interpretation for Fig. 2b: In the base case, QIV was estimated to
lead to the avoidance of $46.5 million in societal costs. When considering the lower and upper bounds of the estimated degree of B lineage cross-
protection, cost offsets were estimated to be A$ 66.2 million and A$ 26.8 million respectively. Lower and higher bounds used in the deterministic
sensitivity analyses are available in Additional file 1. Abbreviations: GP: general practitioner; TIV: trivalent influenza vaccine
Table 5 Results of scenario analyses over 2002–2012 (2009 excluded) for total recommended population (n = 7,423,675)
Total over the period (% variation compared to base case)
Base case Scenario 1 Scenario 2
Outcomes avoided
Influenza cases 68,271 58,468 (−14 %) 68,271 (0 %)
GP consultations 47,537 40,711 (−14 %) 47,537 (0 %)
Working days lost 33,091 28,339 (−14 %) 33,091 (0 %)
Hospitalisations 3,522 3,016 (−14 %) 4,095 (16 %)
Deaths 683 585 (−14 %) 693 (1 %)
Influenza-related cost offsets (in A$)
GP consultations $1,761,250 $1,508,357 (−14 %) $1,761,250 (0 %)
Hospitalisations $34,741,889 $29,750,615 (−14 %) $38,300,256 (10 %)
Income loss $10,010,133 $8,572,811 (−14 %) $10,010,133 (0 %)
Total societal costs $46,513,271 $39,831,784 (−14 %) $50,071,639 (8 %)
GP general practitioner, Scenario 1: Constant attack rate over study period; Scenario 2: Increased risk of hospitalisation and death for population with risk factor
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There are limitations in the available data, common to
most influenza simulation models [47], which affected
our analysis. To address the impact of the following lim-
itations, we conducted a number of scenario analyses
and sensitivity analyses.
Firstly, in the absence of reliable data to estimate the
annual incidence of influenza across age groups for a
given country and period in time, extrapolations were
made in order to derive season-specific incidences over
2002–2012. Because the randomized clinical trials
considered in the calculations of average age-specific in-
fluenza attack rates were not specific to Australia and to
the period of analysis, and because the distribution of
these average rates relied on local surveillance data
which might be biased due to changes in the surveillance
networks over the years, the obtained seasonal
incidences could very well be different from what really
happened in Australia over the period 2002–2012.
Secondly, as no Australian data were available, prob-
abilities of GP consultation following influenza infection
were taken from a US study, while the number of
workdays lost per influenza infection were derived from
European literature. These estimates are likely to be
underestimated since Australia ranks well internationally
in terms of health care accessibility, with nearly 85 %
of Australians consulting a GP at least once a year as
against less than 70 % in the US [48], and also in terms
of social security in general. Moreover, the range of
values tested in the sensitivity analyses were sufficiently
wide to cover the range of estimates reported in the
literature for developed countries, such as the GP
consultation rates considered in Preaud et al. [49] for
people with risk factors in Europe (32–70 %) and the
range of the mean number of working days lost per
episode following physician diagnosis of influenza (3.7–
5.9 days) as reported in an international review [50].
Sensitivity analyses supported the fact that these param-
eters did not have a critical impact on the model out-
comes, with a maximum of 12 % variability around
base case values of societal costs avoided with QIV.
People with risk factors are known to be at in-
creased risk of influenza complications, but there
were no robust data available to estimate the influ-
enza burden for such people. The main analysis, in
which we considered estimates for the general popu-
lation across all age groups, is likely to underestimate
the impact of QIV in people aged 6 months to
64 years with risk factors. We ran a scenario analysis
to provide an estimate of this underestimation, while
also assuming the same influenza strain distribution
for all age groups. If strain distributions specific to
each age group would have been available, the esti-
mated impact of QIV may have been slightly lower
since the majority of hospitalisations and deaths
related to influenza occur in the elderly and in very
young children (<6 months) [3], the latter group not
being directly eligible for influenza vaccination. In-
deed, limited evidence showed that although influenza
B causes disease in all age groups, its incidence rela-
tive to influenza A appears to be highest among older
children and young adults [51, 52]. Finally, resource
use was assumed to be similar for all influenza types,
supported by the findings of a recent prospective
study which found no difference in clinical features
between cases due to influenza type A and type B
over four seasons [53].
Overall, the influenza-related costs avoided, estimated
by the model are likely to be conservative as they do not
reflect the entire economic burden avoided in Australia.
Medical costs of death, medication costs or laboratory
tests, transportation costs as well as potential higher
costs for care delivered in a private setting were omitted,
indirect costs did not include societal costs of premature
death and the loss of working days due to hospitalisa-
tions, and furthermore, the analysis only accounted for
part of the Australian population.
Finally, some additional analyses and improvements of
the model should be considered in future research. Firstly,
vaccination costs that were not taken into account in our
study as we mainly focused on the medical costs and loss
of productivity related to influenza could be included, fol-
lowing which a cost-effectiveness analysis could be con-
ducted taking into consideration the vaccination costs
associated with QIV and TIV. Secondly, because of the
scarcity of local data, we used a static model to estimate
the impact of QIV. Static models are unable to account
for changes in the force of infection arising from the re-
duction in the prevalence of infectious individuals that
can be brought about by vaccination or acquired immun-
ity [54]. These models are only able to capture the impact
of direct protection at the very start of an influenza sea-
son, resulting potentially in the underestimation of the
benefits of vaccination compared to dynamic models. In
addition, static models do not take into account different
contact rates between individuals according to their age or
social characteristics, which have an impact on the trans-
mission of influenza strains across population groups.
However, as dynamic modelling is a complex approach
which requires extensive data, subject to data availability,
a further step could be to refine the estimation of QIV
benefits using a dynamic model.
Conclusions
In Australia, the use of QIV instead of TIV over the
period 2002–2012 could have led to significant reductions
in the number of influenza infections and its related com-
plications, leading to the avoidance of influenza-related
costs. Sensitivity analyses demonstrated that the results
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are mainly driven by the characteristics of influenza circu-
lation and the estimated vaccine effectiveness. The use of
QIV instead of TIV is expected to prevent much
influenza-related burden in years with high B circulation
and mismatch.
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